Sacituzumab Govitecan: First Approval
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy™) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. In April 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzumab govitecan is undergoing phase III development for breast cancer in the USA and EU, and phase II development for urothelial cancer. It is also being explored for brain metastases, glioblastoma, endometrial cancer and prostate cancer. This article summarizes the milestones in the development of sacituzumab govitecan leading to this first approval for mTNBC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874 · cited 11×
“Among 108 patients with mTNBC receiving sacituzumab govitecan in IMMU-132-01, grade 3 AEs occurred in 66% of patients; the most common (incidence ≥ 5”
BackgroundInfluentialGoldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., & Goldenberg, D. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2939 · Cited by 311
Cardillo, T. M., Govindan, S. V., Sharkey, R. M., Trisal, P., Arrojo, R., Liu, D., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5b00223 · Cited by 304
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Trop-2 Is a Determinant of Breast Cancer Survival
Ambrogi, F., Fornili, M., Boracchi, P., Trerotola, M., Relli, V., Simeone, P., La Sorda, R., Lattanzio, R., Querzoli, P., Pedriali, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096993 · Cited by 221
Heist, R. S., Guarino, M. J., Masters, G., Purcell, W. T., Starodub, A. N., Horn, L., Scheff, R. J., Bardia, A., Messersmith, W. A., Berlin, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1894 · Cited by 193
Sharkey, R. M., McBride, W. J., Cardillo, T. M., Govindan, S. V., Wang, Y., Rossi, E. A., Chang, C.-H., & Goldenberg, D. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0670 · Cited by 172
Gray, J. E., Heist, R. S., Starodub, A. N., Camidge, D. R., Kio, E. A., Masters, G. A., Purcell, W. T., Guarino, M. J., Misleh, J., Schneider, C. J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0933 · Cited by 162
Rugo, H. S., Bardia, A., Tolaney, S. M., Arteaga, C. L., Cortés, J., Sohn, J., Marmé, F., Hong, Q., Delaney, R., Hafeez, A., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0163 · Cited by 137
Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 86
Tagawa, S. T., Faltas, B. M., Lam, E. T., Saylor, P. J., Bardia, A., Hajdenberg, J. J., Morgans, A. K., Lim, E. A., Kalinsky, K. M., Simpson, P. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.354 · Cited by 84
Zeybek, B., Manzano, A., Bianchi, A., Bonazzoli, E., Bellone, S., Buza, N., Hui, P., Lopez, S., Perrone, E., Manara, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58009-3 · Cited by 68
Chang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
Lopez, S., Perrone, E., Bellone, S., Bonazzoli, E., Zeybek, B., Han, C., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Bianchi, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27342 · Cited by 51
Perrone, E., Manara, P., Lopez, S., Bellone, S., Bonazzoli, E., Manzano, A., Zammataro, L. A., Bianchi, A., Zeybek, B., Buza, N., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12627 · Cited by 49
Han, C., Perrone, E., Zeybek, B., Bellone, S., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Feinberg, J., Haines, K. E., Karger, M. E. M., et al. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.11.018 · Cited by 44
Cardillo, T. M., Mostafa, A. A., Rossi, D. L., Liu, D., Chang, C., Sharkey, R. M., & Goldenberg, D. M. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-3193 · Cited by 8
Kalinsky, K. M., Isakoff, S. J., Tolaney, S. M., Juric, D., Mayer, I. A., Vahdat, L. T., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p2-11-01 · Cited by 3
Cited by
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Yamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23793-7 · Cited by 309
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy
Tong, J. T. W., Harris, P. W. R., Brimble, M. A., & Kavianinia, I. (2021) · Molecules · doi:10.3390/molecules26195847 · Cited by 287
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
Wang, R., Hu, B., Pan, Z., Mo, C., Zhao, X., Liu, G., Hou, P., Cui, Q., Xu, Z., Wang, W., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01704-3 · Cited by 285
Metadata
- Authors
- Syed, Y. Y.
- Venue
- Drugs
- Published
- 2020-06-11
- Volume
- 80
- Issue
- 10
- Pages
- 1019-1025
- ISSN
- 0012-6667 (ISSN-L)
- 1179-1950
- OpenAlex
- W3035644303
- Cited by
- 293
- References
- 22
- FWCI
- 10.07
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.